Project Details
Description
The objective of this phase I/II study is to determine the maximum tolerated dose of taxol in combination with carboplatin in previously untreated patients with advanced or recurrent non-small cell lung cancer (NSCLC); define the pharmacokinetics of carboplatin with combination therapy and correlate 24 hour total plasma platinum concentration and pharmacodynamic consequences of therapy with carboplatin area under the concentration curve.
| Status | Finished |
|---|---|
| Effective start/end date | 10/1/96 → 9/30/97 |
Fingerprint
Explore the research topics touched on by this project. These labels are generated based on the underlying awards/grants. Together they form a unique fingerprint.